U.S. Markets close in 1 hr 50 mins

4 Pharma Stocks Leading Thursday's Bull Charge

CORAL GABLES, FL / ACCESSWIRE / January 24, 2019 / The pharma stock market was built on the framework and understanding that, as medical experts discover new diseases, companies in the sector are responsible for creating innovative treatment options to combat these ailments. It is for this reason, among many others, that there is an high demand for qualitative healthcare, on both a domestic and global scale. It would serve companies in the healthcare industry well to do everything in their power to champion products meant to help patients feel as healthy as possible, resulting in the creation of potential investor opportunities. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Teligent Inc (TLGT), Inovio Pharmaceuticals Inc (INO), and Aurora Cannabis Inc (NYSE: ACB, TSX: ACB) are 4 pharma stocks to keep tabs on as the industry moves toward the future.

Premier Health Group (OTC:PHGRF) (CSE:PHGI), a company that you may not have heard of, but could potentially benefit from looking into, recognizes the importance of investing in the future of the pharmaceutical industry, and amid this understanding, has made key acquisitions and investments over the last few months to assure the best quality of products/care options for their patients.

Premier Health Group (OTC:PHGRF) (CSE:PHGI) today announced it is moving forward with a binding Letter of Intent ("LOI") to acquire two Metro Vancouver-based pharmacies. The pharmacies were cash flow positive and had combined annual revenue of over $6 million for the fiscal year ended May 31, 2018. Premier Health expects the acquisition to close in or about Q2 2019.

Dr. Essam Hamza, CEO of Premier Health Group (OTC:PHGRF) (CSE:PHGI), said, "We are very excited about this opportunity to acquire two well-run and profitable pharmacies. As part of our patient-centric model, fill and fulfillment is a major component of our telemedicine app. We are also pleased to have the pharmacies' key management team, with over 20 years' experience managing pharmacies, come on board to continue running the operations. We look forward to working together to improve fulfillment for our rapidly growing patient base. In addition, with one of the pharmacies occupying a space of over 6000 square feet, we have a potential opportunity for a brand-new medical clinic expansion."

For More Information On Premier Health Group, Click Here

Teligent Inc (TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Clobetasol Propionate Ointment USP, 0.05%. This is Teligent's first approval of 2019, and its thirty-third approval from its internally-developed pipeline of topical generic pharmaceutical medicines.

In a press release regarding the announcement, Jason Grenfell-Gardner, President and CEO of Teligent, said, "The first approval of 2019 is an important one for Teligent as we continue on our growth trajectory. We now have thirty-eight topical generic pharmaceutical products in the US portfolio, in addition to our four US injectable products."

For More Information On Teligent, Inc, Click Here

Inovio Pharmaceuticals Inc (INO) saw its shares enjoy a 5.65% boost, trading at $5.05 per share just after the strike of noon on Thursday. The Company today announced that a second patient with HPV-related head and neck cancer treated with INO-3112 (now called MEDI0457) in a Phase 1 trial achieved a sustained complete response (full remission) after subsequent treatment with a PD-1 checkpoint inhibitor.

In response to the patient's miraculous recovery, Dr. J. Joseph Kim, Inovio's President, and CEO, said, "Achieving sustained complete responses with immunotherapy in metastatic cancer patients is what you hope for with novel cancer treatments. The fact that the treatment with our synthetic DNA vaccine followed with two different PD-1 inhibitors in this HPV-related cancer patient population showed a complete response in 2 out of 4 progressors is very encouraging as the best complete response rate by PD-1 inhibitors as monotherapy in metastatic head and neck cancer is approximately 4%."

For More Information on Inovio Pharmaceuticals, Inc, Click Here

Aurora Cannabis Inc (ACB), one of several leading cannabis producers working to integrate cannabis as a form of treatment for patients that would otherwise look to traditional pharmaceutical routes, today announced that it has closed its previously announced offering of 5.5% convertible senior notes due 2024 for gross proceeds of US$345 million (including US$45 million pursuant to the exercise of the initial purchasers' over-allotment option). The notes were issued at par value.

Terry Booth, Chief Executive Officer, commented on the announcement, saying that "these convertible notes offer Aurora the flexibility and optionality to settle the entire principal amount of the notes in the future for cash, shares, or combination thereof. The transaction signals confidence in our expected future performance and recognition that we have deployed our shareholders' capital in an intelligent way."

For More Information On Aurora Cannabis, Inc, Click Here

What Is Stock Price (StockPrice.com)?

Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.

StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.

At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 (CASH) for & were paid "500,000" shares of restricted common shares (as of 1/24/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information Please click here for full disclaimer.

Contact Information:

news@stockprice.com

SOURCE: StockPrice.com